Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleMetabolism, Transport, and Pharmacogenomics
Open Access

Delineating the Role of Various Factors in Renal Disposition of Digoxin through Application of Physiologically Based Kidney Model to Renal Impairment Populations

Daniel Scotcher, Christopher R. Jones, Aleksandra Galetin and Amin Rostami-Hodjegan
Journal of Pharmacology and Experimental Therapeutics March 2017, 360 (3) 484-495; DOI: https://doi.org/10.1124/jpet.116.237438
Daniel Scotcher
Centre for Applied Pharmacokinetic Research, School of Health Sciences, University of Manchester, Manchester, United Kingdom (D.S., A.G., A.R.-H.); DMPK, Oncology iMed, AstraZeneca R&D, Alderley Park, Macclesfield, Cheshire, United Kingdom (C.R.J.); and Simcyp Limited (a Certara Company), Blades Enterprise Centre, Sheffield, United Kingdom (A.R.-H.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christopher R. Jones
Centre for Applied Pharmacokinetic Research, School of Health Sciences, University of Manchester, Manchester, United Kingdom (D.S., A.G., A.R.-H.); DMPK, Oncology iMed, AstraZeneca R&D, Alderley Park, Macclesfield, Cheshire, United Kingdom (C.R.J.); and Simcyp Limited (a Certara Company), Blades Enterprise Centre, Sheffield, United Kingdom (A.R.-H.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Aleksandra Galetin
Centre for Applied Pharmacokinetic Research, School of Health Sciences, University of Manchester, Manchester, United Kingdom (D.S., A.G., A.R.-H.); DMPK, Oncology iMed, AstraZeneca R&D, Alderley Park, Macclesfield, Cheshire, United Kingdom (C.R.J.); and Simcyp Limited (a Certara Company), Blades Enterprise Centre, Sheffield, United Kingdom (A.R.-H.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amin Rostami-Hodjegan
Centre for Applied Pharmacokinetic Research, School of Health Sciences, University of Manchester, Manchester, United Kingdom (D.S., A.G., A.R.-H.); DMPK, Oncology iMed, AstraZeneca R&D, Alderley Park, Macclesfield, Cheshire, United Kingdom (C.R.J.); and Simcyp Limited (a Certara Company), Blades Enterprise Centre, Sheffield, United Kingdom (A.R.-H.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Additional Files
  • Figure1
    • Download figure
    • Open in new tab
    • Download powerpoint
  • Fig. 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 1.

    Workflow of the development and application of the PBPK kidney model for digoxin.

  • Fig. 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 2.

    Mean simulated digoxin plasma concentration time profiles (intravenous administration of 1 mg digoxin) for intermediate PBPK models used during development of the mechanistic kidney model. CLR defined by a single input value (136.1 ml/ min) based on the literature analysis (orange line) and CLR simulated using the mechanistic kidney model, accounting for only glomerular filtration (purple line), glomerular filtration and reabsorption (turquoise line), or glomerular filtration, reabsorption, and active secretion (blue line).

  • Fig. 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 3.

    Simulated digoxin CLR (A) and Cmax, PT-1 (B) at different input values for the kidney transporter kinetic parameters. Values of OATP4C1 CLint,T and P-gp REF were varied using the automated sensitivity analysis tool in the SimCYP simulator in a population representative following the clinical trial design reported previously (Greiner et al., 1999). Insets show the graphs presented on logarithmic scales.

  • Fig. 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 4.

    Estimation of OATP4C1 CLint,T parameter using a sensitivity analysis approach by simulating digoxin CLR in population representatives with different serum creatinine values. Colored meshes and gray horizontal plane indicate the simulated CLR and the overall weighted (by subject number) mean CLR obtained from the literature analysis (136.1 ml/min; n = 214 healthy subjects), respectively. Values of OATP4C1 CLint,T and serum creatinine parameters were varied using the automated sensitivity analysis tool in the SimCYP simulator. Optimal OATP4C1 value was taken at the intersection (yellow star) of the simulated digoxin CLR with the observed CLR at a serum creatinine value of 80 µmol/l (which corresponds to simulated GFR ∼120 ml/min), as indicated by the blue arrows. Sensitivity analysis was performed twice using clinical trial designs reported previously (Kramer et al., 1979; Rengelshausen et al., 2003).

  • Fig. 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 5.

    Comparison of simulated and observed digoxin plasma concentration and urinary excretion rate profiles using SimCYP with MechKiM after 0.5 mg by 1 hour infusion (Ochs et al., 1978)(A), 1 mg by 1 hour infusion (Ochs et al., 1978)(B), 1.5 mg by 1 hour infusion (Ochs et al., 1978)(C), 0.75 mg by bolus injection (Johnson and Bye, 1975)(D), and urinary excretion profiles only after 0.4 mg by bolus injection (Lindenbaum et al., 1981)(E) and 0.4 mg by 1 hour infusion (Lindenbaum et al., 1981)(F). Mean (purple solid lines) and 5th and 95th percentiles (dashed purple line) of simulated plasma concentrations are overlaid with mean observed data (purple circles), whereas mean simulated urinary excretion rates (gray solid lines) are overlaid with mean observed data (open circle).

  • Fig. 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 6.

    Simulated CLR in comparison with GFR and OATP4C1 abundance in virtual populations. (A) Simulated CLR and GFR data (purple open circle) in healthy and moderate and severe renal impairment virtual subjects, in comparison with reported clinical data (CLCR data on horizontal axis) (black X) (Bloom et al., 1966; Okada et al., 1978). Solid black line represents linear line of best fit using total least squares regression (which recognizes experimental error in both variables) for the observed clinical data. (B) Simulated CLR and GFR in healthy (yellow solid squares) and moderate (green open circles) and severe (turquoise solid diamond) renal impairment virtual subjects. Solid lines represent linear lines of best fit using ordinary least squares regression for data from each simulation, with relevant equations and R2 shown in boxes.

  • Fig. 7.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 7.

    Impact of reduced renal secretion on simulated digoxin AUC ratio (A), CLR (B) and Cmax,PT-1 ratio (C) in renal impairment populations. Renal secretion was reduced either by changing the kidney OATP4C1 or P-gp relative abundance parameters or by reducing the PTCPGK parameter by a proportional amount. Lines represent changes in PTCPGK in moderate renal impairment (light green solid line) and severe renal impairment (green dashed line), OATP4C1 abundance in moderate renal impairment (light blue solid line) and severe renal impairment (blue dashed line), and P-gp abundance in moderate renal impairment (light purple solid line) and severe renal impairment (purple dashed line). Each scenario was simulated in 100 virtual subjects. Solid horizontal black line (ratio = 1) represents the healthy volunteer population; estimated CLR ratios for the average moderate (GFR = 46.5 ml/min/1.73 m2; orange solid line) and severe (GFR = 23.5 ml/ min/1.73 m2; orange dashed line) renal impairment were calculated based on the correlation of GFR and CLR in the observed data (Bloom et al., 1966; Okada et al., 1978) (A). Relative change of PTCPGK or transporter abundance of 1 indicates that the default moderate or severe renal impairment population in the SimCYP simulator was used

  • Fig. 8.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 8.

    Simulation of digoxin CLR in population representative mode with changes in different systems parameters performed to represent changes in the case of renal impairment. Glomerular filtration rate (range 20–140 ml/min/1.73 m2) was changed by altering the serum creatinine parameter (74.5–695.6 µmol/l); OATP4C1 abundance and PTCPGK parameters were altered by a factor proportional to the relative change in GFR from the population representative of the default "healthy volunteers” population (GFR = 136.4 ml/min/1.73 m2; serum creatinine = 76.5 µmol/l). Lines represent simulations performed with changes in GFR alone (orange dashed line), both GFR and OATP4C1 abundance (blue dashed line), or both GFR and PTCPGK (green dashed lines). Reported clinical data (black X) are overlaid (Bloom et al., 1966; Okada et al., 1978).

Tables

  • Figures
  • Additional Files
    • View popup
    TABLE 1

    Parameters used to simulate digoxin CLR

    Reduction in filtration and secretion was performed to represent changes in renal impairment. Simulated population representative of the “healthy volunteers” population had an age, weight, and body surface area of 20 years, 81 kg, and 1.98 m2, respectively. Serum creatinine (input parameter of model) was calculated for each scenario using the Cockcroft-Gault equation (Cockcroft and Gault, 1976), based on the target GFR and the age, weight, and body surface area of the population representative.

    GFRSerum Creatinine Concentration OATP4C1 AbundancePTCPGK
    ml/min/1.73 m2µmol/lmillion PTC/g kidney
    136.4a76.5160
    14074.51.0361.6
    12086.90.8852.8
    100104.30.7344.0
    80130.40.5935.2
    60173.90.4426.4
    40260.80.2917.6
    20521.70.158.8
    15695.60.116.6
    • ↵a Relative change in GFR for each scenario was calculated using the value of 136.4 ml/ min/m2 as baseline and applied to the OATP4C1 abundance or PTCPGK parameter.

    • View popup
    TABLE 2

    Values of the OATP4C1 CLint,T parameter estimated by various methods and subsequent simulated digoxin CLR in healthy volunteers using the intravenous trial design from Greiner et al. (1999)

    Source of DataOATP4C1 CLint,T Value Simulated Digoxin CLR
    µl/min/million PTCml/min
    In vitro–in vivo extrapolation
     MDCK-OATP4C1 (Mikkaichi et al., 2004)0.2390.6
     CHO-OATP4C1 (Chu et al., 2007)270804.3
    Parameter estimation: Fitting to plasma concentration-time profile
     1 mg, i.v. bolus (n = 12 subjects) (Kramer et al., 1979)8.20
     0.01 mg/kg, i.v. 4 min infusion (n = 12 subjects) (Rengelshausen et al., 2003)1.10
     0.5 mg, i.v. 5 min infusion (n = 12 subjects) (Ding et al., 2004)0
     0.75 mg, i.v. bolus (n = 8 subjects) (Koup et al., 1975)0.09
     0.75 mg, i.v. 1 h infusion (n = 8 subjects) (Koup et al., 1975)5.56
     0.75 mg, i.v. 3 min infusion (n = 8 subjects) (Johnson and Bye, 1975)3.30
     0.5 mg, i.v. 1 h infusion (n = 9 subjects) (Ochs et al., 1978)0
     1 mg, i.v. 1 h infusion (n = 9 subjects) (Ochs et al., 1978)0
     1.5 mg, i.v. 1 h infusion (n = 9 subjects) (Ochs et al., 1978)0
     Overall weighted mean ± standard deviation1.85 ± 2.87108.8
    Parameter estimation: Sensitivity analysis
     Overall weighted mean CLRa (Population representative using trial design 1 mg, i.v. bolus (Kramer et al., 1979))4.14133.4
     Overall weighted mean CLRa (Population representative using trial design 0.01 mg/ kg, i.v. 4 min infusion (Rengelshausen et al., 2003))4.14133.4
    • PTC, proximal tubule cells; MDCK, Madin-Darby canine kidney.

    • ↵a CLR data presented in Supplemental Table S4.

    • View popup
    TABLE 3

    MechKiM parameter values for digoxin model

    Description (units)ValueComment
    fu,kidney0.51Predicted (Rodgers et al., 2005; Rodgers and Rowland, 2006)
    fu,urine1
    OATP4C1 CLint,T (µl/min/million PTC)4.14Estimated using sensitivity analysis Allocated to OAT1/ SLC22A6 transporter in MechKiM as OATP4C1 not defined in model
    OATP4C1 RAF/ REF1
    P-gp Km (µM)177Same as liver/gut (Neuhoff et al., 2013b)
    P-gp Vmax (pmol/min/million PTC)434Same as liver/gut (Neuhoff et al., 2013b)
    P-gp REF1.51Calculated from mRNA expression data (Hilgendorf et al., 2007)
    CLPD (µl/min/million PTC)0.01Estimated using sensitivity analysis and comparing simulated Freab with that predicted using static tubular reabsorption model (Scotcher et al., 2016c) and published Caco-2 data (Neuhoff et al., 2003; Zhang and Morris, 2003; Djuv and Nilsen, 2008; Fossati et al., 2008). Same value for apical and basolateral membranes in all segments of nephron
    • fu,kidney, fraction unbound in kidney; fu,urine, fraction unbound in urine; Freab, fraction reabsorbed; CLint,T, transporter intrinsic clearance; CLPD, permeability diffusion clearance; Km, Michaelis constant; MechKiM, mechanistic kidney model in SimCYP simulator; PTC, proximal tubule cells; RAF, relative activity factor; REF, relative activity factor; Vmax, maximal velocity.

    • View popup
    TABLE 4

    Simulated digoxin CLR and AUC0-∞ parameters in different virtual populations

    Each value represents the mean of 100 simulated individuals taken from the virtual population provided with the SimCYP simulator after a single 0.75 mg i.v. dose.

    PopulationSimulated CLR% of healthy CLRSimulated AUC0-∞% of healthy AUC0-∞
    ml/minµg.min/ml
    Healthy131.91003.36100
    Elderly90.7695.12152
    Moderate renal impairment65.9505.68169
    Severe renal impairment43.8337.00208

Additional Files

  • Figures
  • Tables
  • Data Supplement

    Files in this Data Supplement:

    • Supplemental Data - 5 supplemental tables, 4 figures.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 360 (3)
Journal of Pharmacology and Experimental Therapeutics
Vol. 360, Issue 3
1 Mar 2017
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Delineating the Role of Various Factors in Renal Disposition of Digoxin through Application of Physiologically Based Kidney Model to Renal Impairment Populations
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleMetabolism, Transport, and Pharmacogenomics

PBPK Kidney Model of Digoxin and Renal Impairment

Daniel Scotcher, Christopher R. Jones, Aleksandra Galetin and Amin Rostami-Hodjegan
Journal of Pharmacology and Experimental Therapeutics March 1, 2017, 360 (3) 484-495; DOI: https://doi.org/10.1124/jpet.116.237438

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Research ArticleMetabolism, Transport, and Pharmacogenomics

PBPK Kidney Model of Digoxin and Renal Impairment

Daniel Scotcher, Christopher R. Jones, Aleksandra Galetin and Amin Rostami-Hodjegan
Journal of Pharmacology and Experimental Therapeutics March 1, 2017, 360 (3) 484-495; DOI: https://doi.org/10.1124/jpet.116.237438
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Visual Overview
    • Abstract
    • Introduction
    • Methods
    • Results
    • Discussion
    • Acknowledgments
    • Authorship Contributions
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • HDL Mimetic 4F Modulates Aβ Distribution in Brain and Plasma
  • AOX1 Inhibition by Gefitinib, Erlotinib, and Metabolites
  • Catalytic Activity of CYP2C9 Variants
Show more Metabolism, Transport, and Pharmacogenomics

Similar Articles

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics